Calcification inhibitors in vascular calciphylaxis associated with normal renal function

 

^* These authors contributed equally.

• References

• 1 Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24: 142-148.
• 2 Shanahan CM, Crouthamel MH, Kapustin A. et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
• 3 Nigwekar SU, Wolf M, Sterns RH. et al. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139-1143.
• 4 Ketteler M, Bongartz P, Westenfeld R. et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833.
• 5 Cranenburg EC, Koos R, Schurgers LJ. et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010; 104: 811-822.
• 6 Cranenburg EC, Vermeer C, Koos R. et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008; 45: 427-436.
• 7 Arenas MD, Gil MT, Gutiérrez MD. et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol 2008; 70: 261-264.
• 8 Hristova M, van Beek C, Schurgers LJ. et al. Rapidly progressive severe vascular calcification sparing the kidney allograft following warfarin initiation. Am J Kidney Dis 2010; 56: 1158-1162.
• 9 Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000; 20: 317-327.
• 10 Baldwin C, Farah M, Leung M. et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58: 988-991.